Q4 2023 · 13F-HR
RA CAPITAL MANAGEMENT, L.P.holdings as filed
Filed 2024-02-14 · accession 0001104659-24-023984
$6.40B
Reported value
62
Positions
2023-12-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 04351P101 | ASNDUSD | ASCENDIS PHARMA A/S - ADR | $1.27B | 19.9% | 10,107,400 | Common | SOLE |
| 45253H101 | IMGNEUR | IMMUNOGEN INC | $704.2M | 11.0% | 23,750,601 | Common | SOLE |
| 92243G108 | PCVX | VAXCYTE INC | $495.6M | 7.74% | 7,891,254 | Common | SOLE |
| 52490G102 | LEGN | LEGEND BIOTECH CORP-ADR | $376.9M | 5.89% | 6,264,707 | Common | SOLE |
| 76243J105 | RYTM | RHYTHM PHARMACEUTICALS INC | $245.0M | 3.83% | 5,330,412 | Common | SOLE |
| 008064107 | — | AEROVATE THERAPEUTICS INC | $187.0M | 2.92% | 8,263,982 | Common | SOLE |
| 45720L107 | INBXUSD | INHIBRX INC | $179.5M | 2.80% | 4,724,207 | Common | SOLE |
| 23257D103 | CBAYUSD | CYMABAY THERAPEUTICS INC | $163.9M | 2.56% | 6,940,000 | Common | SOLE |
| 09062X103 | BIIB | BIOGEN INC | $137.9M | 2.15% | 532,892 | Common | SOLE |
| 78349D107 | RXST | RXSIGHT INC | $137.3M | 2.14% | 3,404,285 | Common | SOLE |
| 282559103 | ETNBGBP | 89BIO INC | $127.5M | 1.99% | 11,416,948 | Common | SOLE |
| 925050106 | VRNA | VERONA PHARMA PLC - ADR | $125.6M | 1.96% | 6,317,990 | Common | SOLE |
| 23954D109 | DAWNGBX | DAY ONE BIOPHARMACEUTICALS I | $114.0M | 1.78% | 7,809,852 | Common | SOLE |
| 037326105 | ANTX | AN2 THERAPEUTICS INC | $113.7M | 1.78% | 5,551,295 | Common | SOLE |
| 90240B106 | TYRA | TYRA BIOSCIENCES INC | $100.2M | 1.57% | 7,236,454 | Common | SOLE |
| 47103J105 | JANX | JANUX THERAPEUTICS INC | $98.3M | 1.54% | 9,165,652 | Common | SOLE |
| 374163103 | GERN | GERON CORP | $97.5M | 1.52% | 46,202,425 | Common | SOLE |
| 45114M109 | — | ICOSAVAX INC | $94.0M | 1.47% | 5,963,565 | Common | SOLE |
| 02083G100 | NVLSEUR | ALPINE IMMUNE SCIENCES INC | $93.6M | 1.46% | 4,909,763 | Common | SOLE |
| Y95308105 | WVE | WAVE LIFE SCIENCES LTD | $91.9M | 1.44% | 18,202,009 | Common | SOLE |
| N62509109 | NAMS | NEWAMSTERDAM PHARMA CO NV | $87.8M | 1.37% | 7,864,000 | Common | SOLE |
| 35104E100 | FDMT | 4D MOLECULAR THERAPEUTICS IN | $84.3M | 1.32% | 4,163,211 | Common | SOLE |
| 30050B101 | EVH | EVOLENT HEALTH INC - A | $84.2M | 1.32% | 2,549,132 | Common | SOLE |
| 05464T104 | AXSM | AXSOME THERAPEUTICS INC | $79.6M | 1.24% | 1,000,000 | Common | SOLE |
| 359616109 | FULC | FULCRUM THERAPEUTICS INC | $78.4M | 1.22% | 11,609,704 | Common | SOLE |
| 23285D109 | CTKB | CYTEK BIOSCIENCES INC | $62.1M | 0.97% | 6,809,404 | Common | SOLE |
| 00509G209 | ABOS | ACUMEN PHARMACEUTICALS INC | $57.3M | 0.90% | 14,932,063 | Common | SOLE |
| 713317105 | PEPG | PEPGEN INC | $55.3M | 0.86% | 8,131,952 | Common | SOLE |
| 03770N101 | APGE | APOGEE THERAPEUTICS INC | $55.3M | 0.86% | 1,977,901 | Common | SOLE |
| 82835W108 | SPRY | ARS PHARMACEUTICALS INC | $51.8M | 0.81% | 9,459,678 | Common | SOLE |
| 65487U108 | NKTX | NKARTA INC | $51.5M | 0.80% | 7,805,129 | Common | SOLE |
| 929033108 | — | VOR BIOPHARMA INC | $51.2M | 0.80% | 22,748,880 | Common | SOLE |
| 46565G104 | 5E7 | ITEOS THERAPEUTICS INC | $48.4M | 0.76% | 4,417,259 | Common | SOLE |
| 558868105 | MDGL | MADRIGAL PHARMACEUTICALS INC | $47.3M | 0.74% | 204,500 | Common | SOLE |
| M96088105 | URGN | UROGEN PHARMA LTD | $46.3M | 0.72% | 3,083,430 | Common | SOLE |
| 556099109 | MGNX | MACROGENICS INC | $39.0M | 0.61% | 4,053,077 | Common | SOLE |
| 28658R106 | CLYM | ELIEM THERAPEUTICS INC | $35.5M | 0.55% | 13,150,849 | Common | SOLE |
| 877619106 | TSHA | TAYSHA GENE THERAPIES INC | $32.7M | 0.51% | 18,472,503 | Common | SOLE |
| G3855L106 | GHRS | GH RESEARCH PLC | $32.4M | 0.51% | 5,587,333 | Common | SOLE |
| 29337E102 | ELVN | ENLIVEN THERAPEUTICS INC | $29.4M | 0.46% | 2,122,465 | Common | SOLE |
| 12529R107 | CCCC | C4 THERAPEUTICS INC | $27.6M | 0.43% | 4,878,000 | Common | SOLE |
| 603170101 | MLYS | MINERALYS THERAPEUTICS INC | $27.3M | 0.43% | 3,178,476 | Common | SOLE |
| 95075A107 | HOWL | WEREWOLF THERAPEUTICS INC | $23.7M | 0.37% | 6,144,881 | Common | SOLE |
| 004890109 | ACRV | ACRIVON THERAPEUTICS INC | $23.7M | 0.37% | 4,810,508 | Common | SOLE |
| 729139105 | PLRX | PLIANT THERAPEUTICS INC | $23.2M | 0.36% | 1,281,000 | Common | SOLE |
| 88427A107 | — | THIRD HARMONIC BIO INC | $22.3M | 0.35% | 2,033,056 | Common | SOLE |
| 05370A108 | RNAGBP | AVIDITY BIOSCIENCES INC | $22.2M | 0.35% | 2,454,533 | Common | SOLE |
| 83422E204 | SLDB | SOLID BIOSCIENCES INC | $21.0M | 0.33% | 3,426,286 | Common | SOLE |
| 86366E106 | GPCR | STRUCTURE THERAPEUTICS INC | $19.8M | 0.31% | 486,832 | Common | SOLE |
| 87990A106 | TNYA | TENAYA THERAPEUTICS INC | $17.8M | 0.28% | 5,507,347 | Common | SOLE |
| 04335A105 | ARVN | ARVINAS INC | $17.3M | 0.27% | 421,348 | Common | SOLE |
| 41358P205 | HARPUSD | HARPOON THERAPEUTICS INC | $17.1M | 0.27% | 1,500,000 | Common | SOLE |
| 088786108 | BCYC | BICYCLE THERAPEUTICS PLC-ADR | $14.5M | 0.23% | 800,000 | Common | SOLE |
| N2451R105 | CVAC | CUREVAC NV | $11.6M | 0.18% | 2,744,270 | Common | SOLE |
| 20451W101 | CMPS | COMPASS PATHWAYS PLC | $11.3M | 0.18% | 1,286,000 | Common | SOLE |
| 09203E105 | BDTX | BLACK DIAMOND THERAPEUTICS I | $9.9M | 0.15% | 3,525,754 | Common | SOLE |
| 16934W106 | CMRXEUR | CHIMERIX INC | $8.5M | 0.13% | 8,800,000 | Common | SOLE |
| 449585108 | 1K0 | IGM BIOSCIENCES INC | $7.8M | 0.12% | 937,500 | Common | SOLE |
| 207523101 | — | CONNECT BIOPHARMA HOLDINGS L | $3.6M | 0.06% | 3,062,871 | Common | SOLE |
| 90466Y103 | — | UNICYCIVE THERAPEUTICS INC | $3.0M | 0.05% | 3,470,688 | Common | SOLE |
| 78397T202 | SABS | SAB BIOTHERAPEUTICS INC | $1.6M | 0.03% | 2,374,081 | Common | SOLE |
| N62509117 | NAMSW | NEWAMSTERDAM PHARMA CO NV-27 | $1.0M | 0.02% | 333,333 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.